Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers


1. Ly3502970
1. 2212020-52-3
2. Ly3502970
3. Chembl4446782
4. Ly-3502970
5. 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one
6. 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one
7. V6g
8. Orforglipron [inn]
9. Orforglipron [usan]
10. Ly3502970 (orforglipron)
11. Owl833
12. Schembl21175277
13. Gtpl12175
14. 7zw40d021m
15. Ex-a7751
16. Bdbm50514045
17. Akos040733262
18. Glp-1 Receptor Agonist 1;orforglipron
19. Ms-31635
20. Hy-112185
21. Cs-0043632
22. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4s)-tetrahydro-2,2-dimethyl-2h-pyran-4-yl]-1h-indol-1-yl]-2-methylcyclopropyl]-
23. 3-[(1s,2s)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4s)-2,2-dimethyloxan-4-yl]-1h-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5h)-ide
| Molecular Weight | 883.0 g/mol |
|---|---|
| Molecular Formula | C48H48F2N10O5 |
| XLogP3 | 6.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 144 |
| Heavy Atom Count | 65 |
| Formal Charge | 0 |
| Complexity | 1950 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
4-Fluoro-3,5-dimethylphenylhydrazine hydrochloride
CAS Number : 2212021-40-2
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(2...
CAS Number : 2212021-61-7
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
(2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-...
CAS Number : 2212021-56-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
5-Bromo-4-fluoro-1-methyl-1H-indazole
CAS Number : 1784678-61-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
Ethy 5-Bromoindole-2-carboxylate
CAS Number : 16732-70-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
1-[(1S,2S)-1-cyano-2-methylcyclopropyl]-5-[(4S)-2,...
CAS Number : 2212021-81-1
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1...
CAS Number : 2212021-83-3
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2...
CAS Number : 2415797-61-2
End Use API : Orforglipron Calcium Hydrate
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM se...
5-Bromo-4-fluoro-1-methyl-1H-indazole
CAS Number : 1784678-61-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM se...
(2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-1...
CAS Number : 2212021-56-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM se...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 0.8MG BASE
Packaging :
Approval Date :
Application Number : 220934
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Packaging :
Approval Date :
Application Number : 220934
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5.5MG BASE
Packaging :
Approval Date :
Application Number : 220934
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 9MG BASE
Packaging :
Approval Date :
Application Number : 220934
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 14.5MG BASE
Packaging :
Approval Date :
Application Number : 220934
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 17.2MG BASE
Packaging :
Approval Date :
Application Number : 220934
Regulatory Info :
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 0.8MG BASE
Approval Date :
Application Number : 220934
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date :
Application Number : 220934
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5.5MG BASE
Approval Date :
Application Number : 220934
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 9MG BASE
Approval Date :
Application Number : 220934
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 14.5MG BASE
Approval Date :
Application Number : 220934
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : FOUNDAYO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 17.2MG BASE
Approval Date :
Application Number : 220934
RX/OTC/DISCN :
RLD :
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions
Market Place
Reply
27 Apr 2026
Reply
06 Dec 2025
Reply
11 Jul 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
79
PharmaCompass offers a list of Orforglipron Calcium Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier.
A Orforglipron Calcium Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orforglipron Calcium Hydrate, including repackagers and relabelers. The FDA regulates Orforglipron Calcium Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orforglipron Calcium Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Orforglipron Calcium Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Orforglipron Calcium Hydrate supplier is an individual or a company that provides Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) or Orforglipron Calcium Hydrate finished formulations upon request. The Orforglipron Calcium Hydrate suppliers may include Orforglipron Calcium Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Orforglipron Calcium Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Orforglipron Calcium Hydrate DMFs exist exist since differing nations have different regulations, such as Orforglipron Calcium Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Orforglipron Calcium Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Orforglipron Calcium Hydrate USDMF includes data on Orforglipron Calcium Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orforglipron Calcium Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Orforglipron Calcium Hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Orforglipron Calcium Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orforglipron Calcium Hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Orforglipron Calcium Hydrate suppliers with NDC on PharmaCompass.
Orforglipron Calcium Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orforglipron Calcium Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Orforglipron Calcium Hydrate GMP manufacturer or Orforglipron Calcium Hydrate GMP API supplier for your needs.
A Orforglipron Calcium Hydrate CoA (Certificate of Analysis) is a formal document that attests to Orforglipron Calcium Hydrate's compliance with Orforglipron Calcium Hydrate specifications and serves as a tool for batch-level quality control.
Orforglipron Calcium Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Orforglipron Calcium Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orforglipron Calcium Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Orforglipron Calcium Hydrate EP), Orforglipron Calcium Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orforglipron Calcium Hydrate USP).